Kingdon Capital Management’s Tempest Therapeutics TPST Stock Holding History

Kingdon Capital Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-231	Closed	-$15.6M	–	159
2015 Q2	$19.6M	Sell	231 -36	-13%	-$3.3M	0.77%	42
2015 Q1	$27.1M	Buy	267 +98	+58%	+$13.1M	1.15%	18
2014 Q4	$21.8M	Buy	169 +22	+15%	+$1.61M	0.95%	32
2014 Q3	$7.13M	Sell	147 -12	-8%	-$421K	0.32%	81
2014 Q2	$4.25M	Buy	159 +56	+54%	+$1.32M	0.16%	144
2014 Q1	$2.69M	Buy	+103	New	+$2.92M	0.14%	147

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kingdon Capital Management's TPST Position: Q3 2015 in Review

Kingdon Capital Management sold out of Tempest Therapeutics (TPST) in Q3 2015, closing a stake of 231 shares — an estimated $15.6M sold.

Kingdon Capital Management first reported a position in TPST in Q1 2014 and held it in 6 quarters. The position peaked at $27.1M in Q1 2015. 90 funds tracked by Wall St. Rank hold TPST as of Q3 2015.

Kingdon Capital Management reported no remaining Tempest Therapeutics position as of Q3 2015 after selling out during the quarter.
Kingdon Capital Management sold 231 Tempest Therapeutics shares in Q3 2015, an estimated $15.6M.
Kingdon Capital Management first reported a position in Tempest Therapeutics in Q1 2014 and held it in 6 quarters.
Kingdon Capital Management's Tempest Therapeutics position peaked at $27.1M in Q1 2015.
90 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2015.

Based on Kingdon Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.